Medical & Regulatory Disclaimers

Informational nature of the site

This website is owned by Vantage Point Global CR/SA (Hybrida Farms™) (“Hybrida”), a Costa Rican company engaged in contract cultivation of medical cannabis under Law 10113 (2022).

All content — including service pages, product specifications, blog, formulary, and responses from the Iris assistant — is published for informational and educational purposes only. It is not an offer of sale to the public, nor a substitute for the clinical judgment of a licensed healthcare professional.

Not medical advice

Information presented here must not be used to self-diagnose, self-medicate, initiate, adjust, or discontinue any treatment. Always consult a healthcare professional licensed in your jurisdiction before making clinical decisions.

If you are experiencing a medical emergency, contact local emergency services immediately. In the United States: 9-1-1. In the EU/UK: 112. In Costa Rica: 9-1-1.

United States — FDA statement

These statements have not been evaluated by the U.S. Food and Drug Administration (FDA). The products described are not intended to diagnose, treat, cure, or prevent any disease.

Cannabis containing more than 0.3% THC by dry weight remains a controlled substance under the U.S. federal Controlled Substances Act (CSA). Hybrida does not export, sell, or distribute products into the United States outside applicable federal and state frameworks.

European Union — EMA & EU-GMP

Medical cannabis flower and extracts may only be supplied in the EU under medical prescription and through authorised supply chains, in accordance with Directive 2001/83/EC and EU-GMP guidelines.

Product descriptions on this site do not constitute therapeutic indications approved by the European Medicines Agency (EMA) or any national competent authority.

United Kingdom — MHRA

Medical cannabis products in the United Kingdom are prescribed as Cannabis-Based Products for Medicinal Use (CBPMs) under the oversight of the Medicines and Healthcare products Regulatory Agency (MHRA) and the Home Office. They may only be prescribed by registered specialist physicians on the relevant register.

Australia — TGA

In Australia, medical cannabis products are controlled substances under the Poisons Standard and are accessed primarily via the Therapeutic Goods Administration's Special Access Scheme (SAS) or Authorised Prescriber Scheme (APS). This site does not constitute advertising of prescription medicines.

Canada — Health Canada

In Canada, medical cannabis is regulated under the Cannabis Act and its regulations. Hybrida does not market products directly to Canadian patients; any supply is made to federal licence holders.

Latin America

Costa Rica: dispensing only under prescription from a licensed healthcare professional pursuant to Law 10113.

Mexico (COFEPRIS), Brazil (ANVISA), Colombia (INVIMA), Argentina (ANMAT), and others: access to medical cannabis products is subject to national regulation. This site does not replace those processes nor authorise importation by private individuals.

Other jurisdictions

The legal status of cannabis varies substantially between countries and, within a country, between states or provinces. It is the user's responsibility to verify the legislation applicable in their jurisdiction before acting on any information published on this site.

Hybrida does not encourage, promote, or facilitate the importation or use of cannabis in jurisdictions where doing so would be unlawful.

Scientific references

References to clinical studies, monographs, and professional guidelines are provided for reference only. Inclusion of a reference does not imply endorsement, therapeutic equivalence, or that a specific Hybrida product produces the same clinical effect.

Conversational assistant (Iris)

Iris is an automated assistant trained on Hybrida's public information and general medical cannabis knowledge. Its responses may contain errors or omissions and do not replace the advice of a healthcare, legal, or regulatory professional.

Testimonials & case examples

Any testimonial, clinical case, or outcome mentioned is illustrative. Response to cannabis therapy varies between patients, and no clinical outcome is guaranteed.

Adverse event reporting

If you experience or suspect an adverse reaction to a medical cannabis product, discontinue use, contact your prescriber, and report the event to the relevant health authority (in Costa Rica: Ministry of Health / National Pharmacovigilance Centre; in the U.S.: FDA MedWatch; in the EU: your national competent authority).